



Latest oncology clinical development updates

Tuesday, April 22, 2025

[Subscribe here](#)

[Read this newsletter online](#)


OTW News Highlights this week

- [REVEAL GENOMICS, Ona Therapeutics Partner to Advance ADC Across Multiple Tumor Types](#)
- [Ph 1/2a CARMA study of ELC-301 continues as planned following the safety committee's assessment of cohort 1](#)
- [TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Ph 2b SunRISe-1 study \(Cohort 2\) in NMIBC patients](#)
- [NMPA accepted NDA for zurletrectinib \(ICP-723\) for the treatment of patients with advanced solid tumors harboring NTRK gene fusions](#)
- [nference and BeiGene Collaborate to Drive New B-Cell Cancer Research](#)
- [All clinical development of nemvaleukin to discontinue following review of data from the Ph 2 ARTISTRY-6 and Ph 3 ARTISTRY-7 trials](#)
- [Enhertu + pertuzumab in DESTINY-Breast09 Ph 3 trial demonstrated PFS improvement in vs THP as a 1L treatment for patients with HER2-positive metastatic breast cancer](#)
- [FDA Clears IND Application for CLD-201 in Solid Tumors](#)

- [Blenrep \(belantamab mafodotin\) combinations approved by UK MHRA in R/R multiple myeloma](#)



[Read more Drug Approvals](#)



[Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas](#)

“Receiving the Rare Pediatric Disease Designation for NEO100 is a crucial step forward in our mission to develop effective treatments for children facing diffuse high-grade gliomas,” said Dr. Thomas Chen, CEO and Chief Science Officer of NeOnc Technologies Holdings, Inc. “This designation not only validates the potential of our research but also strengthens our commitment to delivering innovative therapies that ...

[RMAT Designation for LYL314 for the Treatment of R/R Large B-Cell Lymphoma](#)

"The RMAT designation for LYL314, is based on promising clinical data from our ongoing Phase 1/2 trial and highlights the transformative potential of this next-generation CAR T-cell therapy to address the unmet needs of patients with aggressive large B-cell lymphoma," said Lynn Seely, M.D., president and chief executive officer of Lyell. "We believe that by targeting both CD19 and CD20 ...

[Read more Regulatory News](#)



[Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks](#)

"We are pleased with these recent study results, giving patients an opportunity to access the therapy in an open-label setting," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "CTCL is an incredibly difficult to treat orphan disease and remains an area of unmet medical need with a very limited number of safe and effective therapies. Following ...

[Preliminary results from Ph 2 IPAX-Linz study of TLX101 \(131I-iodofalan1\) in recurrent high-grade glioma announced](#)

Dr. David Cade, Chief Medical Officer at Telix, said, "These are encouraging results, offering new options for patients with historically poor outcomes. We are grateful to Dr. Pichler and his team for building on the IPAX-1 study in a more advanced and complex study cohort that is also representative of a real-world patient population."

[Read more Trial Results](#)




[First Patient Treated in Ph 1 Trial of PHST001 for Patients with Advanced Solid Tumors](#)

“The start of this Phase 1 trial is an important milestone for Pheast and for the advancement of next generation macrophage checkpoint therapies,” said Roy Maute, Ph.D., Cofounder and CEO, Pheast Therapeutics. “We believe PHST001 has the potential to provide new treatment options for patients, particularly in cancers where other immunotherapies have not been effective.”

[Enrollment completed in Ph 2 CRDF-004 Trial of Onvansertib for the Treatment of 1L RAS-mutated Metastatic CRC](#)

“The successful completion of enrollment in our first-line trial for patients with RAS mutant mCRC represents an important milestone in our mission to develop new treatments for a population who have not seen meaningful treatment advancements for decades. We are deeply grateful for our patients, care-givers and clinical investigators, whose commitment to the trial has been integral in this achievement,” ...

[Read more Trial Status](#)



[Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital](#)

"Under the terms of the agreement, Oncolytics has the right to sell, and Alumni has the obligation to purchase up to US\$20 million worth of common stock over a 15-month period at prices that are based on the market price at the time of each sale to Alumni. Oncolytics, at its sole discretion, controls the timing and amount of all ...

[Sumitomo Pharma America enters into a CRADA with the NCI to Advance Clinical Understanding of Enzomenib](#)

"We are highly encouraged by the preliminary data showing promising clinical activity of enzomenib in patients with relapsed/refractory acute leukemia, and with the support and partnership of the National Cancer Institute, we are poised to continue this positive momentum by expanding exploration of its application across additional cancers," said Jatin Shah, M.D., Chief Medical Officer, Oncology, SMPA. "We're honored to ...

[Read more Business News](#)

Editor's Desk

Editor's Desk

Author

- [Richa Tewari, PhD](#)

Managing Editors

- [Shalini Roy Choudhury, PhD](#)
- [Anusha Jayaraman, PhD](#)

Social Media Managers

- [Siftjit Kaur, PhD](#)
- [Himanshi Agarwal, PhD](#)



Disclaimer: The OTW team take care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is a part of RLS Consultants, which is a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.
